Abstract
24 chromosome aneuploidy testing have been introduced for pre-selection of embryos with improved potential to result in clinical pregnancy. This has a unique potential to combine with PGD for monogenic disorders, as the testing can be done in the same biopsy material, avoiding the risk for trisomy in the pre-selected genetic disease free embryos. So the first experience of systematic PGD with concomitant testing for single gene disorders, HLA typing and 24 chromosome testing is presented, involving the application of this novel approach to 55 different genetic conditions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
